Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19876879 | 0.91 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL31384028 | 0.89 | TDP1 (0.59) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL12903540 | 0.82 | MAPT (0.50) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL29956339 | 0.82 | MAPT (0.50) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL138261 | 0.82 | SMN1; SMN2 (0.83) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL4947409 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| Hydrochloric Acid SCHEMBL9905725 | 0.80 | SMN1; SMN2 (0.79) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL14357958 | 0.80 | MAPT (0.79) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL31533187 | 0.80 | SMN1; SMN2 (0.79) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 | |
| SCHEMBL31171174 | 0.80 | SMN1; SMN2 (0.79) | SMN1; SMN2MAPTLIN28ATDP1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052135-B1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIV OSLO (NO) | 2018-07-18 | — | — | EP | disclosed |
| US-8133474-B2 | Porphyrin chelate compound that may be complexed with zinc, manganese, magnesium, iron or aluminum; capable of insertion into cell; zinc, calcium, mercury, cadmium, and lead analytes; determining shift in signal; medical diagnosis | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133474-B2 | Porphyrin chelate compound that may be complexed with zinc, manganese, magnesium, iron or aluminum; capable of insertion into cell; zinc, calcium, mercury, cadmium, and lead analytes; determining shift in signal; medical diagnosis | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-03-13 | — | — | US | disclosed |
| US-7875258-B2 | For use as radiopharmaceuticals; solid phase synthesis; conjugation with DNA and G-protein-coupled receptors; high binding affinity, high labeling yield, superior retention and versatility; labeling without the need for co-ligands; simplification | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090023787-A1 | TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080138292-A1 | Sensors for fluorescence and magnetic resonance imaging | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080138292-A1 | Sensors for fluorescence and magnetic resonance imaging | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138292-A1 | Sensors for fluorescence and magnetic resonance imaging | CA2, SLC30A6, SLC39A3 | SMN1; SMN2 876/4885MAPT 1124/4885LIN28A 2643/4885 |
| US-20090023787-A1 | TECHNETIUM-DIPYRIDINE COMPLEXES, AND METHODS OF USE THEREOF | SLC7A5, SLC7A1, AADAT | SMN1; SMN2 4102/4885MAPT 2979/4885LIN28A 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.